Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Lets Context Stand In Open Payments Database

This article was originally published in The Gray Sheet

Executive Summary

Device firm representatives were pleased, at least on first review, with CMS’ presentation of the industry-submitted physician payment data posted online for the first time Sept. 30, including the public context provided for the database.

You may also be interested in...



New Sunshine Rules In The EU, And How They Compare To US Requirements

Two EU member states are introducing new sunshine rules to boost transparency. Is the EU following the US lead? Attorneys Hein van den Bos and Ron Wisor discuss EU trends and US burdens.

Companies Dig Into Sunshine Rule Details In Preparation For Aug. 1 Go-Live Date

CMS has finalized several sunshine rule provisions: the definition of “applicable manufacturer” has been narrowed; many payments to speakers at continuing medical education programs and events need not be reported; and the agency will allow manufacturers to supply contextual information on the public database.

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel